Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.52 USD | -1.15% | -4.71% | -15.27% |
Financials (USD)
Sales 2024 * | 632M | Sales 2025 * | 708M | Capitalization | 2.87B |
---|---|---|---|---|---|
Net income 2024 * | 109M | Net income 2025 * | 148M | EV / Sales 2024 * | 3.49 x |
Net cash position 2024 * | 659M | Net cash position 2025 * | 748M | EV / Sales 2025 * | 2.99 x |
P/E ratio 2024 * |
28.6
x | P/E ratio 2025 * |
21.4
x | Employees | 352 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.18% |
Latest transcript on Corcept Therapeutics Incorporated
1 day | -1.15% | ||
1 week | -4.71% | ||
Current month | +18.01% | ||
1 month | +20.70% | ||
3 months | +13.95% | ||
6 months | +8.90% | ||
Current year | -15.27% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Belanoff
FOU | Founder | 66 | 98-05-12 |
Atabak Mokari
DFI | Director of Finance/CFO | 47 | 21-02-28 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 46 | 12-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Belanoff
FOU | Founder | 66 | 98-05-12 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-03-11 |
George Baker
BRD | Director/Board Member | 81 | 98-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.71% | 28 M€ | -1.64% | ||
0.30% | 43 M€ | +3.46% | ||
0.27% | 25 M€ | -2.72% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 27.52 | -1.15% | 594,697 |
24-05-23 | 27.84 | -2.73% | 596,591 |
24-05-22 | 28.62 | -0.62% | 578,543 |
24-05-21 | 28.8 | -0.28% | 547,807 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.27% | 2.87B | |
+38.51% | 727B | |
+31.74% | 594B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.44% | 205B | |
-5.97% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- CORT Stock